Tech Company Financing Transactions
CytoDyn Funding Round
CytoDyn closed a $30 million funding round on 11/3/2025. Investors included Yorkville Advisors.
Transaction Overview
Company Name
Announced On
11/3/2025
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1111 Main Street 660
Vancouver, WA 98660
USA
Vancouver, WA 98660
USA
Phone
Website
Email Address
Overview
CytoDyn is committed to enhancing the lives of patients through target specific medicine. Our team is focused on developing leronlimab, a monoclonal antibody CCR5 receptor antagonist, as a platform drug with potential in a variety of indications in solid-tumor oncology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jacob Lalezari
Browse more venture capital transactions:
Prev: 11/3/2025: Locksley Resources venture capital transaction
Next: 11/4/2025: DeepJudge venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs